WO1994017211A1 - Non-radioactive method for detecting a labelled segment and a solution or composition therefor - Google Patents

Non-radioactive method for detecting a labelled segment and a solution or composition therefor Download PDF

Info

Publication number
WO1994017211A1
WO1994017211A1 PCT/US1994/001224 US9401224W WO9417211A1 WO 1994017211 A1 WO1994017211 A1 WO 1994017211A1 US 9401224 W US9401224 W US 9401224W WO 9417211 A1 WO9417211 A1 WO 9417211A1
Authority
WO
WIPO (PCT)
Prior art keywords
complex
solution
alkaline phosphatase
antibody
ligand
Prior art date
Application number
PCT/US1994/001224
Other languages
French (fr)
Inventor
Dennis Wright
Original Assignee
Dennis Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dennis Wright filed Critical Dennis Wright
Priority to AU62349/94A priority Critical patent/AU6234994A/en
Priority to EP94909532A priority patent/EP0701626A4/en
Priority to CA002155028A priority patent/CA2155028C/en
Publication of WO1994017211A1 publication Critical patent/WO1994017211A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2326/00—Chromogens for determinations of oxidoreductase enzymes
    • C12Q2326/90—Developer
    • C12Q2326/92—Nitro blue tetrazolium chloride, i.e. NBT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/50—Indoles
    • C12Q2334/52—5-Bromo-4-chloro-3-indolyl, i.e. BCI
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/938—Hydrolases (3) acting on glycosyl compounds (3.2) acting on beta-galactose-glycoside bonds, e.g. beta-galactosidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a non-radioactive method and a solution or composition for the detection of a ligand and antiligand complex of a DNA or RNA nucleic acid, an antigen, a hapten, a protein, an analyte, an antibody, or an antibody complex wherein the complex is labelled with alkaline phospha ⁇ tase or a tracer having alkaline phosphatase conjugated thereto, and reacted with bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) to produce a colored formazan or a color change indicative of the presence of the labelled complex.
  • BCIP bromo-chloro-indolyl phosphate
  • PMS phenazine methosulfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • Labelling a segment of a DNA or RNA nucleic acid, a protein, a hapten, an antigen, an analyte, an antibody or an antibody complex such that the same can be later identified and detected is desirable in many applications, including diagnostic application of probe technologies.
  • Assay systems which are both rapid and sensitive have been developed to determine the concentration of a substance, for example an analyte, present in low concentration in a fluid sample.
  • Immunoassays depend on the binding of an antigen or hapten to a specific antibody and have been particularly useful because they give high levels of specificity and sensitivity.
  • Such assays may employ a reagent in labelled form referred to as the tracer.
  • labelling nucleic acids include nick translation, primer extension, methods based on RNA polymerase, end-labelling methods, and direct labelling methods.
  • the need for resolution and sensitivity determines the choice of label to DNA or RNA nucleic acid, proteins, or antibodies.
  • Labels for probes are usually radioactive.
  • Biotin is a commonly used non-radioactive label for probes which can be incorporated into polynucleotide enzymatically using biotinylated nucleotide as the substrate.
  • a photoactivatable analogue of biotin upon brief irradiation with visible light may be used to form stable linkages with both single and double stranded nucleic acids.
  • Biotin-labelled probes are detected through a variety of signal generating systems usually using avidin, a glycoprotein with an extremely high affinity for biotin, or streptavidin, an avidin- like protein. Alternatively, it has been known to label DNA with digoxigenin-labelled deoxyuridine triphosphate. After hybridization to the target DNA, the hybrids are detected by enzyme-linked immunoassay using an antibody conjugate such as biotin-conjugated with alkaline phosphatase.
  • Non-radioactive labels with biotin have lower sensitivity in comparison with radioactive labels.
  • radioactive probes are used for most commercial applications of hybridization technologies requiring that probes be freshly prepared at regular intervals due to radioisotopes having short half-lives.
  • Radioactive labels also require special safety precautions for the isotopes and proper radioactive waste disposal.
  • Enzymes have also often been used as labels in immunoassay.
  • EIA enzyme immunoassay
  • an enzyme is covalently conjugated with one component of a specifically binding antigen-antibody pair, and the resulting enzyme conjugate is reacted with a substrate to produce a signal which is detected and measured.
  • the signal may be a colour change, detected with the naked eye or by a spectrophotometric technique, or may be conversion of the substrate to a product detected by fluorescence.
  • a convenient format for EIA is solid phase immunoassay in which one of the assay reagents is immobilized on a solid support usually in the form of a dip stick, the inside wall of a test tube or cuvette, the well of a microtiter plate, or a microporous membrane.
  • the final step in most membrane EIA procedures is contacting a color developing reagent, such as a chromogen, with the membrane.
  • the chromogen reacts with enzyme captured on the membrane to produce a colored product which may be detected as evidence of the presence of analyte or measured as evidence of the concentration of analyte.
  • Tetrazolium salts have been used for analytical purposes in the detection of reduced nicotinamideadenine dinucleotide (NADH) wherein the transference of hydrogen is catalyzed not only by enzymes, such as diaphorase, but also by 5- methylphenazinium methylsulphate (PMS) or similar substances, to thereby form deep colored formazans as a reduction indicator. Therefore, appropriate processes have been developed in this way to detect a series of substances which are important in analytical chemistry, via the NADH produced as an intermediate.
  • NADH nicotinamideadenine dinucleotide
  • PMS 5- methylphenazinium methylsulphate
  • Tetrazolium salts conventionally employed in dehydrogenase procedures include 3-(4.5'-dimethylthiazolyl-2)- 2,4-diphenyltetrazolium bromide (MTT), 2-(p-iodophenyl)-3-(p- nitrophenyl)-5-phenyl-tetrazolium chloride (INT), 2,2' ,5,5'- tetra- (p-nitrophenyl)-3 , 3-( 3-dimethoxy-4-diphenylene)- ditetrazolium chloride (TNBT), 2,2'-di-(p-nitrophenyl)-5.5'- diphenyl-3 , 3 '-dimethoxy-4, 4 '-diphenylene)-ditetrazolium chloride (NBT) , 2 , 2 ' -p-diphenylene-3 , 3 ' , 5.5 ' - tetraphenylditetrazolium chloride (neotetrazolium chloride) (
  • United States Patent Nos. 4,613,569 and 4,867,196 to Giesler et al. are directed to a stabilized composition of tetrazolium salts containing one to ten moles of a complex- forming acid, such as boric acid or organic hydroxypolylcarboxylic acid, which is soluble in polar solvents per mole of tetrazolium salt.
  • a complex- forming acid such as boric acid or organic hydroxypolylcarboxylic acid
  • the stabilizing agents are employed in previously known test systems in which the tetrazolium salts are used as indicators such as dehydrogenase procedures involving the detection of lactic acid with lactate dehydrogenase, alcohol with alcohol dehydrogenase, glycerol with glycerol dehydrogenase, glucose with glucose dehydrogenase, acetaldehyde with acetaldehyde dehydrogenase, as well as further systems which can be coupled to the above system.
  • the present invention provides for a non-radioactive method of detecting (as well as a solution and composition therefor) a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto which comprises reacting the complex with bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) and allowing the reaction to proceed to reduce the dimethylthiazol diphenyl tetrazolium (MTT) and form a colored formazan or produce a color change indicative of the presence of the labelled complex.
  • BCIP bromo-chloro-indolyl phosphate
  • PMS phenazine methosulfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • a non-radioactive method of detecting a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto comprising reacting said complex with bromo-chloro-indolyl phosphate (BCIP), phenazine methosfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) and allowing the reaction to proceed to produce a colored formazan or a color change indicative of the presence of said labelled complex.
  • BCIP bromo-chloro-indolyl phosphate
  • PMS phenazine methosfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • the present invention also provides for a solution or composition, as well as a test kit including the same, used in the method of detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested that comprises a mixture of bromo-chloro- indolyl phosphate (BCIP), phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) which, when the solution added to said test sample or the composition dissolved in solution and added to the test sample, is capable of producing a colored formazan or a color change indicative of the presence of said labelled complex.
  • BCIP bromo-chloro- indolyl phosphate
  • PMS phenazine methosulfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • FIG. 1 illustrates a non-radioactive prior art technique for detection of a labelled and hybridized DNA segment using an antibody-conjugate of antidigoxigenin and alkaline phosphatase in an enzyme-catalyzed color reaction with bromo-chloro-indolyl phosphate (BCIP) and nitroblue tetrazolium salt (NBT) .
  • BCIP bromo-chloro-indolyl phosphate
  • NBT nitroblue tetrazolium salt
  • FIG. 2 illustrates the non-radioactive technique of the present invention for the detection of a labelled and hybridized DNA segment using an antibody-conjugate of antidigoxigenin and alkaline phosphatase but in a color reaction based on bromo-chloro-indolyl phosphate (BCIP) in admixture with catalyst phenazine metholsulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT).
  • BCIP bromo-chloro-indolyl phosphate
  • PMS catalyst phenazine metholsulfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • the present invention provides a non-radioactive method for detection of a ligand and antiligand complex of DNA or RNA nucleic acid, a hapten, an antigen, a protein, an antibody, an antibody complex, or an analyte which is labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto wherein the labelled complex is detected in a color reaction with bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS, N-methylphenazoniummethosulfate, C 14 H 14 N 2 0 4 S, molecular weight 306.34, mp 158-160° (dec), ⁇ max 386nm, Merck Index 11,6024, FT-IR 1(2),885A), and dimethylthiazol diphenyl tetrazolium (MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
  • bromo-chloro-indolyl phosphate also referred to as BCIP
  • BCIP includes 5-bromo-4-chloro 3-indolyl phosphate (BCIP, crystalline, disodium salt, C 8 H 4 BrClN0 4 PNa 2 • H 2 0, molecular weight 370.44, mp > 300°) or 5-bromo-4-chloro-2-indolyl phosphate (crystalline, disodium salt, C ⁇ H 4 BrClN0 4 PNa 2 • H 2 0, molecular weight 397.5) or 5-bromo-4-chloro-3-indolyl phosphate • toluidine (powder, 4-toluidine salt, C 8 H 6 N0 4 BrCIP • C 7 H 9 N, molecular weight 433.6).
  • the chromogenic detection of present invention may be implemented in an assay wherein the ligand may be a RNA nucleic acid probe and the tracer may be a complimentary strand of RNA or DNA conjugated with alkaline phosphatase.
  • the ligand may be a protein or antigen using an alkaline phosphatase label or a tracer conjugated with alkaline phosphatase.
  • the ligand may be an analyte or an antibody or an antibody complex using an alkaline phosphatase label or a tracer conjugated with alkaline phosphatase.
  • Assay procedures involving either direct incorporation of alkaline phosphatase to a ligand or a tracer having alkaline phosphatase conjugated thereto are well known in the art, and so long as alkaline phosphatase is present, the detection method.of the present invention involving reacting the ligand-antiligand complex with bromo-chloro-indolyl phosphate (BCIP) and dimethylthiazol diphenyl tetrazolium (MTT) catalyzed by phenazine methosulfate (PMS) will provide a reliable chromogenic detection of the presence and concentration of the applicable labelled segment.
  • BCIP bromo-chloro-indolyl phosphate
  • MTT dimethylthiazol diphenyl te
  • membranes such as glass fiber, polyvinylidene difluoride, polycarbonate, nitrocellulose and nylon having a ligand bound thereto may be treated with a solution of a tracer with alkaline phosphatase.
  • the tracer may be an antiligand having alkaline phosphatase conjugated to the ligand wherein the assay is performed by conventional sandwich or half sandwich technique.
  • a preferred detection antiligand would be alkaline phosphatase which binds to an antiligand captured on the membrane and thereby affixes the ligand to the membrane surface in direct proportion to the quantity of antiligand in the sample.
  • the ligand may be conjugated by conventional methods to a binder such as biotin, avidin and streptavidin and the latter bound to the antibodies.
  • the detection method of the present invention provides a chromogenic determination of the presence of the alkaline phosphatase segment by reacting the ligand-antiligand complex with bromo-chloro-indolyl phosphate (BCIP) and dimethylthiazol diphenyl tetrazolium (MTT) catalyzed by phenazine methosulfate (PMS) to form a purple or deep color formazan or produce a color change.
  • BCIP bromo-chloro-indolyl phosphate
  • MTT dimethylthiazol diphenyl tetrazolium
  • PMS phenazine methosulfate
  • the ligand or antiligand for use with the chromogenic indication of the present invention may be from any source and each may be selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten.
  • the antiligand is an antibody specific for that antigen.
  • the ligand is a hapten, then the antibody preferably is an antibody specific for the hapten.
  • the ligand is an antibody, preferably the antiligand is an antigen specific for the antibody.
  • the antiligand is preferably an antibody specific for the protein.
  • the antiligand is preferably an antibody specific for the protein.
  • the ligand is a nucleic acid, then preferably the antiligand is a complementary nucleic acid specific for that nucleic acid. If the ligand is an antibody complex, then the antiligand is preferably an antigen specific for that antibody complex.
  • the ligand may be an endocrine hormone, such as HCG or FSH, present in body fluid, or it may be isolated from body fluid and subsequently introduced into a different liquid, such as a buffer.
  • the ligand may be from a source other than a body fluid, as, for example, a culture of microorganisms such as Chlamydia or a cellar extract thereof.
  • Antibodies, such as the antibody against Ly e disease may be assayed, or the ligand may be a hapten such as a therapeutic drug or a drug of abuse.
  • the ligand may also be a protein such as glycoprotein 120 useful in HIV testing.
  • Preferred ligands are antigens, most preferably viral antigens present in a body fluid, such as Adenovirus, Parainfluenza 3 virus.
  • Adenovirus such as Adenovirus, Parainfluenza 3 virus.
  • Assay techniques involving the chromogenic indication of the present invention may also be performed by competitive assay wherein the ligand and tracer compete for antiligand binding sites.
  • a ligand directly labelled with alkaline phosphatase and a tracer selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten may compete for binding sites on the antiligand.
  • the competitive assay may be a procedure wherein a ligand selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten and a tracer having alkaline phosphatase conjugated thereto compete for binding sites on the antiligand.
  • alkaline phosphatase tracer format alkaline phosphatase becomes affixed to the membrane surface in inverse proportion to the quantity of ligand in the sample and the absence of colored formazan is indicative of ligand in the sample.
  • Labelling of ligands with alkaline phosphatase, or labelling of a tracer having alkaline phosphatase conjugated thereto to form a ligand-antiligand complex is well known in the art and deemed to be within the purview of one skilled in the art.
  • BCIF bromo-chloro- indolyl phosphate
  • PMS catalyst phenazine metholsulfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • the present invention of chromogenic detection of a ligand-antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto may be practiced by reacting the complex with a combined mixture containing bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) .
  • a combined mixture may further include a buffer, such as distilled water or a buffer of a mixture in solution of Tris-HCl or Tris-base, sodium chloride (NaCl), and magnesium chloride (MgCl 2 ).
  • the buffer has a pH of about 7 to about 11, with 9.5 being a more preferred pH.
  • the present invention includes a solution or composition for practice of the method, as well as a test kit including such solution or composition.
  • a solution for the detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested comprises a mixture of bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) which when added to said test sample is capable of producing a colored formazan or a color change indicative of the presence of the labelled complex.
  • BCIP bromo-chloro-indolyl phosphate
  • PMS phenazine methosulfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • Such a solution preferably contains equal amounts of phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) in combination with an excess amount of bromo-chloro- indolyl phosphate (BCIP).
  • the ratio of bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) respectively in either solution or composition is preferably about 6:1:1 by weight.
  • a preferred example of the solution would include from about 35 to 50 microliters (hereinafter "ul" ) of bromo-chloro- indolyl phosphate (BCIP) from a 50 mg/ml aqueous solution, from about 70 to 100 ul of phenazine methosulfate (PMS) from a lOmM aqueous solution, and from about 70 to 100 ul of dimethylthiazol diphenyl tetrazolium (MTT) from a lOmM aqueous solution.
  • ul bromo-chloro- indolyl phosphate
  • PMS phenazine methosulfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • BCIP bromo- chloro-indolyl phosphate
  • PMS phenazine methosulfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • the solution may further include a buffer such as distilled water or a buffer which is a mixture in solution of Tris-HCl or Tris-base, sodium chloride (NaCl), and magnesium chloride (MgCl 2 ) .
  • the buffered solution preferably has a pH of about 7 to about 11 with a 9.5 pH being more preferred.
  • the solution of the present invention when reacted with a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested is capable of producing a colored formazan or a sufficient color change indicative of the presence and/or concentration of the labelled complex within fifteen minutes of contacting the test sample at ambient temperature. The intensity or degree of color change is sufficient to accurately determine visually or instrumentally the presence and/or concentration of the labelled complex in the test sample.
  • the present invention also includes a composition for the detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested comprising a powder o compressed solid or a tablet mixture of bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) which, when dissolved in solution and added to said test sample, is capable of producing a colored formazan or a color change indicative of the presence of the labelled complex.
  • BCIP bromo-chloro-indolyl phosphate
  • PMS phenazine methosulfate
  • MTT dimethylthiazol diphenyl tetrazolium
  • Bromo-chloro-indolyl phosphate BCIP
  • phenazine methosulfate PMS
  • dimethylthiazol diphenyl tetrazolium MTT
  • these powdered ingredients may be compressed into solid form or tableted with an inert carrier, preferably an inert carrier which is soluble in water, such as mannitol, by compression or other techniques for tableting known in the tableting arts.
  • the powder or compressed solid or tablet mixture of the composition of the present invention preferably contains approximately equal amounts of phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) in combination with an excess of bromo-chloro-indolyl phosphate (BCIP).
  • the ratio of bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) respectively in such preferred composition is about 6:1:1 by weight.
  • the present invention may also include a kit of materials for performing the method of detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto disclosed herein that comprises a solution vial of, or a composition packet of, bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) in an amount sufficient, when reacted with said labelled complex, to produce a colored formazan or a color change indicative of the presence of the labelled complex.
  • a kit of materials for performing the method of detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto disclosed herein that comprises a solution vial of, or a composition packet of, bromo-chloro-indolyl
  • EXAMPLE I A comparison was made between a prior art nonradioactive DNA labelling and detection method based on a BCIP and NBT chromogenic determination to the method of the present invention in two separate test protocols.
  • each method used a Southwestern blot procedure in general accordance with the protocol of Boehringer Mannheim Corporation (Indianapolis, Indiana) Nonradioactive DNA Labeling and Detection Kit (Catalogue number 1093 657).
  • DNA was labelled for both the prior art method and the method of the present invention by random primed incorporation of digoxigenin- labelled deoxyuridine-triphosphate.
  • the dUTP was linked via a spacer-arm to the steroid hapten digoxigenin (Dig-dUTP).
  • the labelling reaction was fast (1 hour) and resulted in Digoxigenin incorporation every 20-25 nucleotide in the newly synthesized DNA.
  • the first of the present invention chromogenic determinations used an equivalent of 0.00175 grams BCIP, 0.00214438 grams phenazine methosulfate (PMS), and 0.00290031 grams dimethylthiazol diphenyl tetrazolium (MTT).
  • BCIP, PMS, and MTT with the alkaline phosphatase labelled DNA resulted in the formation of a deep purple formazan within one minute and the reaction was stopped in one and a half minutes as background color started to appear.
  • the second chromogenic determination in accordance with the present invention used the same amount of BCIP, namely an equivalent of 0.00175 grams, but reduced the amount of PMS and MTT by a factor of ten, namely an equivalent of 0.000214438 grams PMS and an equivalent of 0.000290031 grams MTT.
  • This second reaction of BCIP, PMS, and MTT with the alkaline phosphatase labelled DNA resulted in the formation of a deep purple formazan within fifteen minutes and the reaction was stopped in twenty minutes as background color started to appear.
  • DNA labelling 1 ug (microgram) of linear DNA was labelled per standard reaction via the control and experimental procedure below.
  • the linearized DNA was purified by phenol/chloroform extraction and ethanol precipitation.
  • the DNA was denaturated by heating for 10 min at 95°C and chilling quickly on ice.
  • the tube was incubated for one hour at 37°C. Longer incubation (up to 20 h) can increase the amount of labelled DNA.
  • the reaction was stopped by adding 2 ul EDTA solution, 0.2 mol/1, pH 8.0, to the tube.
  • the labelled DNA was precipitated with 2 ul LiCl, 4 mol/1, and 60 ul prechilled (-20°C) ethanol, mixed well. 7. The tube was left for 2 hours at -20°C.
  • the tube was centrifuged (at 12000 g); the pellet was washed with cold ethanol 70% (v/v), and dried under vacuum and dissolve in 50 ul Tris-HCl. 10 mmol/1; EDTA, 1 mmol/1; pH 8.0.
  • Nitrocellulose membrane filters were prepared by pre- soaking in IPTG and then air dried on Whatman filter paper. 2. The plaques to be probed were transferred to a nitrocellulose membrane by standard Southwestern transfer plaque lift. 3. The DNA probe was labelled according to the standard assay procedure (section I). 4. The filters were then used directly for detection of hybridized DNA rather than stored air-dried for later detection.
  • BCIP-NBT method of detection and the present invention BCIP-NBT method of detection and the present invention
  • Buffer 1 Tris-HCl, 100 mmol/1; NaCl., 150 mmol/1; pH 7.5
  • Buffer 3 Tris-HCl, 100 mmol/1; NaCl, 100 mmol/1; MgCl 2 , 50 mmol/1; pH 9.5 (20°C); and
  • the first test of the BCIP-PMS-MTT chromogenic detection in accordance with the present invention used a solution
  • the second test of the BCIP-PMS-MTT chromogenic detection of the present invention used a solution (freshly prepared) of 35 ul BCIP (50 mg/ml), 70 ul PMS (lOmM), and 70 ul MTT (lOmM) added to 10 ml buffer 3 above.
  • the antibody-conjugate was diluted to 150mU/ml (1:5000) in buffer 1. (Dilute antibody-conjugate solutions are stable only for about 12 hours at +4°C). 3. The filters were incubated for 30 min with about 40 ml of diluted antibody-conjugate solution. 4. Unbound antibody-conjugate was removed by washing 2 x 15 in with 100 ml of buffer 1.
  • nitrocellulose filters were incubated with ca. 10 ml color solution.
  • Each of the two standard BCIP-NBT detection method tests resulted in the formation of a purple formazan visible to the naked eye in approximately four hours and the reaction was then stopped although the reaction could have been allowed to continue to completion in 24 hours up to three days.
  • the first detection test using the solution containing the greater amounts of PMS and MTT with the same amount of BCIP resulted in a deep purple formazan within one minute and the reaction was then stopped in one and a half minutes as background color started to appear.
  • this first detection protocol used an equivalent of 0.00175 grams BCIP (an excess amount), 0.00214438 grams PMS, and 0.00290031 grams MTT.
  • the second detection test of the present invention which used a solution with one tenth of the amount of PMS and MTT previously used (with the same amount of BCIP), resulted in a purple formazan visible by the naked eye in fifteen minutes and the reaction was stopped in twenty minutes as background color started to appear. It is noted that for this second detection test the amount of MTT and PMS used was approximately one-tenth of the amount of NBT used. Specifically, the second test protocol performed used an equivalent of 0.00175 grams BCIP (an excess amount), 0.000214438 grams PMS, and 0.000290031 grams MTT whereas the prior art detection protocol used an equivalent of
  • This experiment utilized the aqueous stock solutions of alkaline phosphatase, PMS, and MTT described in Example II above.
  • Four spots of 5 ul of alkaline phosphatase solution was added to separate locations of one sheet of Whatman filter.
  • 5 ul of BCIP an excess amount
  • the addition of NBT left a yellowish stain but did not result in the formation of a color formazan within one hour.
  • spot 2 alkaline phosphatase and BCIP. This resulted in the formation of a dark purple formazan complex at the spot in less than one minute.
  • spot number 3 having no BCIP was added 5 ul of MTT, which resulted in a yellowish stain on the spot.
  • spot number 4 was added 5 ul of BCIP and 5 ul of MTT which left a yellowish stain to the previously white paper but did not result in the formation of a colored formazan after one hour.
  • EXAMPLE IV This is a prophetic example relating to the identification of proteins synthesized by recombinant gene.
  • a cloned bacteria such as E-coli is grown and transferred to nitrocellulose paper or, alternatively, an extraction of proteins from a cloned bacteria is performed by SDS-gel.
  • the E-coli is lysed with chloroform or, alternatively, a western blotting of proteins on the nitrocellulose paper is performed which results in protein being affixed to the nitrocellulose paper from lysed bacteria or SDS-gel respectively.
  • the protein can be a protein of metabolized drug of abuse or a protein of a viral disease.
  • a first antibody for example an antibody specific for glycoprotein 120 or the antibody against Lyme disease
  • a second antibody such as a blotting grade conjugate of goat anti-mouse IgG, goat anti-rabbit IgG, or goat anti-human IgG, conjugated with alkaline phosphatase is bound to the first antibody-protein complex to form a first and second antibody and alkaline phosphatase complex.
  • a positive detection of the protein is made by the addition of a solution of BCIP and MTT and PMS to the complex sufficient to generate a chromogenic deep color change or a purple/blue formazan indicative of the presence and concentration of the protein.
  • the method of detection of the present invention has great sensitivity, namely 10 minu " 1S power, and the reaction, which can be completed in approximately twenty minutes, produces a purple formazan or a color change visible by the naked eye in from less than five minutes to approximately fifteen minutes compared to conventional BCIP-NBT detection techniques sensitive to 10 m ⁇ nu ⁇ 12 power which may take many hours or over a day to complete and four or more hours to visually observe.
  • the present invention requires no radioisotope labelling and its sensitivity and specificity makes it useful for hybridization techniques where radioactive labelling and autoradiography are normally required.
  • the method of detection of the present invention can be used for nucleic acid transfers for colony, plaque, in vitro, and in situ hybridizations including standard Southern, Northern, Western, and Southwestern blotting techniques provided such transfers or techniques utilize alkaline phosphatase for chromogenic detection.
  • the present invention may not require use of amplification techniques.
  • the present invention requires no stabilizing agent for the tetrazolium salt and produces an irreversible reaction.
  • the present invention is cost and economy advantageous as it may use only one-tenth of certain chemicals in solution compared to prior art techniques.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A non-radioactive method of detecting a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto comprises reacting the complex with bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) and allowing the reaction to proceed to produce a colored formazan or a color change indicative of the presence of the labelled complex. A solution or composition of bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT), as well as a test kit including the same, is also provided for carrying out the chromogenic method of detection.

Description

NON-RADIOACTIVE METHOD FOR DETECTING A LABELLED SEGMENT AND A SOLUTION OR COMPOSITION THEREFOR
TECHNICAL FIELD
The present invention relates to a non-radioactive method and a solution or composition for the detection of a ligand and antiligand complex of a DNA or RNA nucleic acid, an antigen, a hapten, a protein, an analyte, an antibody, or an antibody complex wherein the complex is labelled with alkaline phospha¬ tase or a tracer having alkaline phosphatase conjugated thereto, and reacted with bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) to produce a colored formazan or a color change indicative of the presence of the labelled complex. BACKGROUND ART
Labelling a segment of a DNA or RNA nucleic acid, a protein, a hapten, an antigen, an analyte, an antibody or an antibody complex such that the same can be later identified and detected is desirable in many applications, including diagnostic application of probe technologies.
Assay systems which are both rapid and sensitive have been developed to determine the concentration of a substance, for example an analyte, present in low concentration in a fluid sample. Immunoassays depend on the binding of an antigen or hapten to a specific antibody and have been particularly useful because they give high levels of specificity and sensitivity. Such assays may employ a reagent in labelled form referred to as the tracer.
For example, five basic methods of labelling nucleic acids include nick translation, primer extension, methods based on RNA polymerase, end-labelling methods, and direct labelling methods. In many probe technologies, the need for resolution and sensitivity determines the choice of label to DNA or RNA nucleic acid, proteins, or antibodies. Labels for probes are usually radioactive. Biotin is a commonly used non-radioactive label for probes which can be incorporated into polynucleotide enzymatically using biotinylated nucleotide as the substrate. Alternatively, a photoactivatable analogue of biotin upon brief irradiation with visible light may be used to form stable linkages with both single and double stranded nucleic acids. Biotin-labelled probes are detected through a variety of signal generating systems usually using avidin, a glycoprotein with an extremely high affinity for biotin, or streptavidin, an avidin- like protein. Alternatively, it has been known to label DNA with digoxigenin-labelled deoxyuridine triphosphate. After hybridization to the target DNA, the hybrids are detected by enzyme-linked immunoassay using an antibody conjugate such as biotin-conjugated with alkaline phosphatase.
Non-radioactive labels with biotin have lower sensitivity in comparison with radioactive labels. Thus, radioactive probes are used for most commercial applications of hybridization technologies requiring that probes be freshly prepared at regular intervals due to radioisotopes having short half-lives. Radioactive labels also require special safety precautions for the isotopes and proper radioactive waste disposal.
Enzymes have also often been used as labels in immunoassay. In conventional enzyme immunoassay (EIA) , an enzyme is covalently conjugated with one component of a specifically binding antigen-antibody pair, and the resulting enzyme conjugate is reacted with a substrate to produce a signal which is detected and measured. The signal may be a colour change, detected with the naked eye or by a spectrophotometric technique, or may be conversion of the substrate to a product detected by fluorescence. A convenient format for EIA is solid phase immunoassay in which one of the assay reagents is immobilized on a solid support usually in the form of a dip stick, the inside wall of a test tube or cuvette, the well of a microtiter plate, or a microporous membrane. The final step in most membrane EIA procedures is contacting a color developing reagent, such as a chromogen, with the membrane. The chromogen reacts with enzyme captured on the membrane to produce a colored product which may be detected as evidence of the presence of analyte or measured as evidence of the concentration of analyte. Tetrazolium salts have been used for analytical purposes in the detection of reduced nicotinamideadenine dinucleotide (NADH) wherein the transference of hydrogen is catalyzed not only by enzymes, such as diaphorase, but also by 5- methylphenazinium methylsulphate (PMS) or similar substances, to thereby form deep colored formazans as a reduction indicator. Therefore, appropriate processes have been developed in this way to detect a series of substances which are important in analytical chemistry, via the NADH produced as an intermediate. Tetrazolium salts conventionally employed in dehydrogenase procedures include 3-(4.5'-dimethylthiazolyl-2)- 2,4-diphenyltetrazolium bromide (MTT), 2-(p-iodophenyl)-3-(p- nitrophenyl)-5-phenyl-tetrazolium chloride (INT), 2,2' ,5,5'- tetra- (p-nitrophenyl)-3 , 3-( 3-dimethoxy-4-diphenylene)- ditetrazolium chloride (TNBT), 2,2'-di-(p-nitrophenyl)-5.5'- diphenyl-3 , 3 '-dimethoxy-4, 4 '-diphenylene)-ditetrazolium chloride (NBT) , 2 , 2 ' -p-diphenylene-3 , 3 ' , 5.5 ' - tetraphenylditetrazolium chloride (neotetrazolium chloride) (NT) and 2,3,5-triphenyltetrazolium chloride (TT). United States Patent Nos. 4,613,569 and 4,867,196 to Giesler et al. are directed to a stabilized composition of tetrazolium salts containing one to ten moles of a complex- forming acid, such as boric acid or organic hydroxypolylcarboxylic acid, which is soluble in polar solvents per mole of tetrazolium salt. The stabilizing agents are employed in previously known test systems in which the tetrazolium salts are used as indicators such as dehydrogenase procedures involving the detection of lactic acid with lactate dehydrogenase, alcohol with alcohol dehydrogenase, glycerol with glycerol dehydrogenase, glucose with glucose dehydrogenase, acetaldehyde with acetaldehyde dehydrogenase, as well as further systems which can be coupled to the above system.
The present invention provides for a non-radioactive method of detecting (as well as a solution and composition therefor) a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto which comprises reacting the complex with bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) and allowing the reaction to proceed to reduce the dimethylthiazol diphenyl tetrazolium (MTT) and form a colored formazan or produce a color change indicative of the presence of the labelled complex. DISCLOSURE OF INVENTION
According to the present invention there is provided a non-radioactive method of detecting a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto comprising reacting said complex with bromo-chloro-indolyl phosphate (BCIP), phenazine methosfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) and allowing the reaction to proceed to produce a colored formazan or a color change indicative of the presence of said labelled complex. The present invention also provides for a solution or composition, as well as a test kit including the same, used in the method of detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested that comprises a mixture of bromo-chloro- indolyl phosphate (BCIP), phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) which, when the solution added to said test sample or the composition dissolved in solution and added to the test sample, is capable of producing a colored formazan or a color change indicative of the presence of said labelled complex.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates a non-radioactive prior art technique for detection of a labelled and hybridized DNA segment using an antibody-conjugate of antidigoxigenin and alkaline phosphatase in an enzyme-catalyzed color reaction with bromo-chloro-indolyl phosphate (BCIP) and nitroblue tetrazolium salt (NBT) .
FIG. 2 illustrates the non-radioactive technique of the present invention for the detection of a labelled and hybridized DNA segment using an antibody-conjugate of antidigoxigenin and alkaline phosphatase but in a color reaction based on bromo-chloro-indolyl phosphate (BCIP) in admixture with catalyst phenazine metholsulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT).
MODES FOR CARRYING OUT THE INVENTION
While this invention is satisfied by embodiments in many different forms, there will herein be described in detail preferred embodiments of the invention, with the understanding that the present disclosure is to be considered as exemplary of the principles of the invention and is not intended to limit the invention to the embodiments described. The scope of the invention will be measured by the appended claims and their equivalence. The present invention provides a non-radioactive method for detection of a ligand and antiligand complex of DNA or RNA nucleic acid, a hapten, an antigen, a protein, an antibody, an antibody complex, or an analyte which is labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto wherein the labelled complex is detected in a color reaction with bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS, N-methylphenazoniummethosulfate, C14H14N204S, molecular weight 306.34, mp 158-160° (dec), λmax 386nm, Merck Index 11,6024, FT-IR 1(2),885A), and dimethylthiazol diphenyl tetrazolium (MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl- 2H-tetrazolium bromide, C18H16N5SBr, molecular weight 414.33, mp 195° (dec), λmax 378nm, NMR 2,(2),501D, FT-IR 1(2),633B). As used herein bromo-chloro-indolyl phosphate, also referred to as BCIP, includes 5-bromo-4-chloro 3-indolyl phosphate (BCIP, crystalline, disodium salt, C8H4BrClN04PNa2 • H20, molecular weight 370.44, mp > 300°) or 5-bromo-4-chloro-2-indolyl phosphate (crystalline, disodium salt, CβH4BrClN04PNa2 • H20, molecular weight 397.5) or 5-bromo-4-chloro-3-indolyl phosphate • toluidine (powder, 4-toluidine salt, C8H6N04BrCIP • C7H9N, molecular weight 433.6).
For example, contrary to the known non-radioactive method for detection of an antibody hapten complex illustrated in FIG. 1 of a biotin-labelled DNA using avidin and alkaline phosphatase which employs a signal generating system of nitroblue tetrazolium (NBT) in a mixture with 5-bromo 4-chloro 3-indolyl phosphate (BCIP), the present invention, as illustrated at FIG. 2, detects a antibody hapten complex of a labelled hybridized segment of DNA conjugated with alkaline phosphatase by a reaction with a mixture of 5-bromo 4-chloro 3- indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT). When alkaline phosphatase in the system illustrated at FIG. 2 reacts with 5- bromo 4-chloro 3-indolyl phosphate (BCIP) and dimethylthiazol diphenyl tetrazolium (MTT) in the presence of a phenazine methosulfate (PMS) catalyst, the dimethylthiazol diphenyl tetrazolium (MTT) serves as a hydrogen acceptor and is converted to MTTH2, a colored purple insoluble formazan complex in stoichiometric quantities which indicates a positive reaction and the presence and concentration of a labelled nucleic segment.
While immunoassay for a DNA hapten as described above and illustrated at Fig. 2 is a preferred application of the invention, one skilled in the art will immediately recognize that the method may be used in many assay procedures. For example, the chromogenic detection of present invention may be implemented in an assay wherein the ligand may be a RNA nucleic acid probe and the tracer may be a complimentary strand of RNA or DNA conjugated with alkaline phosphatase. Alternatively, the ligand may be a protein or antigen using an alkaline phosphatase label or a tracer conjugated with alkaline phosphatase. Still further, the ligand may be an analyte or an antibody or an antibody complex using an alkaline phosphatase label or a tracer conjugated with alkaline phosphatase. Assay procedures involving either direct incorporation of alkaline phosphatase to a ligand or a tracer having alkaline phosphatase conjugated thereto are well known in the art, and so long as alkaline phosphatase is present, the detection method.of the present invention involving reacting the ligand-antiligand complex with bromo-chloro-indolyl phosphate (BCIP) and dimethylthiazol diphenyl tetrazolium (MTT) catalyzed by phenazine methosulfate (PMS) will provide a reliable chromogenic detection of the presence and concentration of the applicable labelled segment. Therefore, membranes such as glass fiber, polyvinylidene difluoride, polycarbonate, nitrocellulose and nylon having a ligand bound thereto may be treated with a solution of a tracer with alkaline phosphatase. The tracer may be an antiligand having alkaline phosphatase conjugated to the ligand wherein the assay is performed by conventional sandwich or half sandwich technique. A preferred detection antiligand would be alkaline phosphatase which binds to an antiligand captured on the membrane and thereby affixes the ligand to the membrane surface in direct proportion to the quantity of antiligand in the sample. Alternatively, the ligand may be conjugated by conventional methods to a binder such as biotin, avidin and streptavidin and the latter bound to the antibodies. In any event, the detection method of the present invention provides a chromogenic determination of the presence of the alkaline phosphatase segment by reacting the ligand-antiligand complex with bromo-chloro-indolyl phosphate (BCIP) and dimethylthiazol diphenyl tetrazolium (MTT) catalyzed by phenazine methosulfate (PMS) to form a purple or deep color formazan or produce a color change.
The ligand or antiligand for use with the chromogenic indication of the present invention may be from any source and each may be selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten. Preferably, if the ligand is an antigen, then the antiligand is an antibody specific for that antigen. Likewise, if the ligand is a hapten, then the antibody preferably is an antibody specific for the hapten. If the ligand is an antibody, preferably the antiligand is an antigen specific for the antibody. If the ligand is a protein, then the antiligand is preferably an antibody specific for the protein. If the ligand is a nucleic acid, then preferably the antiligand is a complementary nucleic acid specific for that nucleic acid. If the ligand is an antibody complex, then the antiligand is preferably an antigen specific for that antibody complex.
For example, the ligand may be an endocrine hormone, such as HCG or FSH, present in body fluid, or it may be isolated from body fluid and subsequently introduced into a different liquid, such as a buffer. In other cases, the ligand may be from a source other than a body fluid, as, for example, a culture of microorganisms such as Chlamydia or a cellar extract thereof. Antibodies, such as the antibody against Ly e disease, may be assayed, or the ligand may be a hapten such as a therapeutic drug or a drug of abuse. The ligand may also be a protein such as glycoprotein 120 useful in HIV testing. Preferred ligands are antigens, most preferably viral antigens present in a body fluid, such as Adenovirus, Parainfluenza 3 virus. Herpes simplex virus (HSV), Respiratory syncytial virus (RSV), and Influenza A (Flu A).
Assay techniques involving the chromogenic indication of the present invention may also be performed by competitive assay wherein the ligand and tracer compete for antiligand binding sites. For example a ligand directly labelled with alkaline phosphatase and a tracer selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten may compete for binding sites on the antiligand. Alternatively, the competitive assay may be a procedure wherein a ligand selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten and a tracer having alkaline phosphatase conjugated thereto compete for binding sites on the antiligand. In the latter alkaline phosphatase tracer format, alkaline phosphatase becomes affixed to the membrane surface in inverse proportion to the quantity of ligand in the sample and the absence of colored formazan is indicative of ligand in the sample.
Labelling of ligands with alkaline phosphatase, or labelling of a tracer having alkaline phosphatase conjugated thereto to form a ligand-antiligand complex is well known in the art and deemed to be within the purview of one skilled in the art.
One may, for example, utilize the detection method of the present invention for the identification of a protein synthesized by a recombinant gene by growing cloned bacteria and transferring the same to a membrane, lysing the bacteria with chloroform, binding the first antibody with a protein, and binding a second antibody with a tracer conjugated with alkaline phosphatase such that the presence and concentration of a positive clone-first antibody protein is detected by a color reaction resultant from admixture with bromo-chloro- indolyl phosphate (BCIF), catalyst phenazine metholsulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT).
The present invention of chromogenic detection of a ligand-antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto may be practiced by reacting the complex with a combined mixture containing bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) . Such a combined mixture may further include a buffer, such as distilled water or a buffer of a mixture in solution of Tris-HCl or Tris-base, sodium chloride (NaCl), and magnesium chloride (MgCl2). Preferably, the buffer has a pH of about 7 to about 11, with 9.5 being a more preferred pH.
In addition to the method set forth above, the present invention includes a solution or composition for practice of the method, as well as a test kit including such solution or composition. A solution for the detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested comprises a mixture of bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) which when added to said test sample is capable of producing a colored formazan or a color change indicative of the presence of the labelled complex. Such a solution preferably contains equal amounts of phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) in combination with an excess amount of bromo-chloro- indolyl phosphate (BCIP). The ratio of bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) respectively in either solution or composition is preferably about 6:1:1 by weight. A preferred example of the solution would include from about 35 to 50 microliters (hereinafter "ul" ) of bromo-chloro- indolyl phosphate (BCIP) from a 50 mg/ml aqueous solution, from about 70 to 100 ul of phenazine methosulfate (PMS) from a lOmM aqueous solution, and from about 70 to 100 ul of dimethylthiazol diphenyl tetrazolium (MTT) from a lOmM aqueous solution. This preferred solution allows for a more controlled production of colored formazan or color change which is particularly beneficial when working with multiple test samples using alkaline phosphatase as a label. However, a solution which would include from about 35 to 50 microliters of bromo- chloro-indolyl phosphate (BCIP) from a 50 mg/ml aqueous solution, from about 100 to 700 ul of phenazine methosulfate (PMS) from a lOmM aqueous solution, and from about 100 to 700 ul of dimethylthiazol diphenyl tetrazolium (MTT) from a lOmM aqueous solution will be sufficient to more quickly produce a colored formazan or color change in reaction with an alkaline phosphatase labelled complex. The solution may further include a buffer such as distilled water or a buffer which is a mixture in solution of Tris-HCl or Tris-base, sodium chloride (NaCl), and magnesium chloride (MgCl2) . The buffered solution preferably has a pH of about 7 to about 11 with a 9.5 pH being more preferred. The solution of the present invention when reacted with a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested is capable of producing a colored formazan or a sufficient color change indicative of the presence and/or concentration of the labelled complex within fifteen minutes of contacting the test sample at ambient temperature. The intensity or degree of color change is sufficient to accurately determine visually or instrumentally the presence and/or concentration of the labelled complex in the test sample.
The present invention also includes a composition for the detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested comprising a powder o compressed solid or a tablet mixture of bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) which, when dissolved in solution and added to said test sample, is capable of producing a colored formazan or a color change indicative of the presence of the labelled complex. Bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) naturally exist in a powdered form and may be packaged together in a powder mixture. Alternatively, these powdered ingredients may be compressed into solid form or tableted with an inert carrier, preferably an inert carrier which is soluble in water, such as mannitol, by compression or other techniques for tableting known in the tableting arts. The powder or compressed solid or tablet mixture of the composition of the present invention preferably contains approximately equal amounts of phenazine methosulfate (PMS) and dimethylthiazol diphenyl tetrazolium (MTT) in combination with an excess of bromo-chloro-indolyl phosphate (BCIP). The ratio of bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) respectively in such preferred composition is about 6:1:1 by weight.
The present invention may also include a kit of materials for performing the method of detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto disclosed herein that comprises a solution vial of, or a composition packet of, bromo-chloro-indolyl phosphate (BCIP), phenazine methosulfate (PMS), and dimethylthiazol diphenyl tetrazolium (MTT) in an amount sufficient, when reacted with said labelled complex, to produce a colored formazan or a color change indicative of the presence of the labelled complex.
The following examples are provided to further describe the invention but are in no way to be considered as limitative of the invention.
EXAMPLE I A comparison was made between a prior art nonradioactive DNA labelling and detection method based on a BCIP and NBT chromogenic determination to the method of the present invention in two separate test protocols.
With the exception of the chromogenic determination step, each method used a Southwestern blot procedure in general accordance with the protocol of Boehringer Mannheim Corporation (Indianapolis, Indiana) Nonradioactive DNA Labeling and Detection Kit (Catalogue number 1093 657). DNA was labelled for both the prior art method and the method of the present invention by random primed incorporation of digoxigenin- labelled deoxyuridine-triphosphate. The dUTP was linked via a spacer-arm to the steroid hapten digoxigenin (Dig-dUTP). The labelling reaction was fast (1 hour) and resulted in Digoxigenin incorporation every 20-25 nucleotide in the newly synthesized DNA. This density of haptens in the DNA resulted in a high sensitivity in the prior art detection reaction, and an even significantly higher degree of sensitivity in the detection reaction of the present invention. After hybridization to the target DNA, the hybrids were detected by enzyme-linked immunoassay using an antibody-conjugate (anti¬ digoxigenin alkaline phosphatase conjugate, <Dig>AP) and a subsequent enzyme-catalyzed color reaction. Specifically, two prior art color reactions were initiated at alkaline pH with an equivalent of 0.00175 grams of 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and an equivalent of 0.003 grams of nitroblue tetrazolium salt (NBT), each of which resulted in the formation of a blue precipitate which was only slightly observable by the naked eye in approximately four hours. Each of the two prior art color reactions of BCIP and NBT could have continued for up to three days, but each reaction was terminated after four hours. Each of the BCIP and NBT prior art reactions were performed in comparison to two color reactions performed in accordance with the teachings of the present invention. The first of the present invention chromogenic determinations used an equivalent of 0.00175 grams BCIP, 0.00214438 grams phenazine methosulfate (PMS), and 0.00290031 grams dimethylthiazol diphenyl tetrazolium (MTT). This reaction of BCIP, PMS, and MTT with the alkaline phosphatase labelled DNA resulted in the formation of a deep purple formazan within one minute and the reaction was stopped in one and a half minutes as background color started to appear. The second chromogenic determination in accordance with the present invention used the same amount of BCIP, namely an equivalent of 0.00175 grams, but reduced the amount of PMS and MTT by a factor of ten, namely an equivalent of 0.000214438 grams PMS and an equivalent of 0.000290031 grams MTT. This second reaction of BCIP, PMS, and MTT with the alkaline phosphatase labelled DNA resulted in the formation of a deep purple formazan within fifteen minutes and the reaction was stopped in twenty minutes as background color started to appear.
For all assays, DNA labelling and experimental procedure was performed substantially in accordance with the following standard Southwestern blot technique and appropriate vials of Boehringer Mannheim Corporation (Indianapolis, Indiana) Nonradioactive DNA Labeling and Detection Kit (Catalogue number 1093 657):
I. DNA labelling: 1 ug (microgram) of linear DNA was labelled per standard reaction via the control and experimental procedure below.
1. The linearized DNA was purified by phenol/chloroform extraction and ethanol precipitation.
2. The DNA was denaturated by heating for 10 min at 95°C and chilling quickly on ice.
3. The following was added to a microfuge tube on ice:
1 ug of freshly denatured DNA, corresponding to 5 control- DNA (vial 2);
2 ul hexanucleotide mixture (vial 5); 2 ul dNPT labeling mixture (vial 6);
1 ul Klenow enzyme (vial 7); and 19 ul deionized water.
4. The tube was incubated for one hour at 37°C. Longer incubation (up to 20 h) can increase the amount of labelled DNA.
5. The reaction was stopped by adding 2 ul EDTA solution, 0.2 mol/1, pH 8.0, to the tube.
6. The labelled DNA was precipitated with 2 ul LiCl, 4 mol/1, and 60 ul prechilled (-20°C) ethanol, mixed well. 7. The tube was left for 2 hours at -20°C.
8. The tube was centrifuged (at 12000 g); the pellet was washed with cold ethanol 70% (v/v), and dried under vacuum and dissolve in 50 ul Tris-HCl. 10 mmol/1; EDTA, 1 mmol/1; pH 8.0.
II. Experimental Procedure:
1. Nitrocellulose membrane filters were prepared by pre- soaking in IPTG and then air dried on Whatman filter paper. 2. The plaques to be probed were transferred to a nitrocellulose membrane by standard Southwestern transfer plaque lift. 3. The DNA probe was labelled according to the standard assay procedure (section I). 4. The filters were then used directly for detection of hybridized DNA rather than stored air-dried for later detection.
The above labelling and plaque transfer steps are known in the art. Immunological detection of the labelled and hybridized sample preparations were made in accordance with the following protocol.
III. Immunological detection: Four buffer solutions were prepared and used for the prior art
BCIP-NBT method of detection and the present invention BCIP-
PMS-MTT method of detection:
(1) Buffer 1: Tris-HCl, 100 mmol/1; NaCl., 150 mmol/1; pH 7.5
(20°C); (2) Buffer 2: Blocking reagent, standard 5% non-fat dried milk
(blotto buffer);
(3) Buffer 3: Tris-HCl, 100 mmol/1; NaCl, 100 mmol/1; MgCl2, 50 mmol/1; pH 9.5 (20°C); and
(4) Buffer 4: Tris-HCl, lOmmol/l; EDTA, 1 mmol/1; pH 8 (20°C). Each of the two solutions (freshly prepared) of BCIP-NBT consisted of 45 ul NBT-solution (vial 9) and 35 ul 5-bromo-4- chloro-3-indolyl phosphate solution added to 10 ml buffer 3 above.
The first test of the BCIP-PMS-MTT chromogenic detection in accordance with the present invention used a solution
(freshly prepared) of 35 ul BCIP (50 mg/ml), 700 ul PMS (lOmM), and 700 ul MTT (lOmM) added to 10 ml buffer 3 above.
The second test of the BCIP-PMS-MTT chromogenic detection of the present invention used a solution (freshly prepared) of 35 ul BCIP (50 mg/ml), 70 ul PMS (lOmM), and 70 ul MTT (lOmM) added to 10 ml buffer 3 above.
The following control and experimental procedures were used in all of the comparative samples, the only difference being the type of and amount of chromogenic agent added to provoke the detection.
Control and experimental procedure.
1. The nitrocellulose filters were washed briefly (1 min) in buffer 1. The filters were then blocked with buffer 2.
2. The antibody-conjugate was diluted to 150mU/ml (1:5000) in buffer 1. (Dilute antibody-conjugate solutions are stable only for about 12 hours at +4°C). 3. The filters were incubated for 30 min with about 40 ml of diluted antibody-conjugate solution. 4. Unbound antibody-conjugate was removed by washing 2 x 15 in with 100 ml of buffer 1.
5. Equilibration of membranes was performed for 2 min with 20 ml of buffer 3.
6. The nitrocellulose filters were incubated with ca. 10 ml color solution.
7. When the desired spots were detected, the reaction was stopped by washing the membrane for 2 minutes with 15-20 ml of buffer 4.
8. The filters were placed on Whatman filter paper and allowed to dry at room temperature.
The following results were obtained relative to the detection: IV. Results:
Each of the two standard BCIP-NBT detection method tests resulted in the formation of a purple formazan visible to the naked eye in approximately four hours and the reaction was then stopped although the reaction could have been allowed to continue to completion in 24 hours up to three days. The first detection test using the solution containing the greater amounts of PMS and MTT with the same amount of BCIP resulted in a deep purple formazan within one minute and the reaction was then stopped in one and a half minutes as background color started to appear. Specifically, this first detection protocol used an equivalent of 0.00175 grams BCIP (an excess amount), 0.00214438 grams PMS, and 0.00290031 grams MTT. The second detection test of the present invention, which used a solution with one tenth of the amount of PMS and MTT previously used (with the same amount of BCIP), resulted in a purple formazan visible by the naked eye in fifteen minutes and the reaction was stopped in twenty minutes as background color started to appear. It is noted that for this second detection test the amount of MTT and PMS used was approximately one-tenth of the amount of NBT used. Specifically, the second test protocol performed used an equivalent of 0.00175 grams BCIP (an excess amount), 0.000214438 grams PMS, and 0.000290031 grams MTT whereas the prior art detection protocol used an equivalent of
0.00175 grams BCIP (an excess amount), and 0.003 grams NBT.
EXAMPLE II In addition to the usage of the present invention with a nucleic acid/protein/antibody system of Example I above, a test was made of the reaction of four varying test samples having alkaline phosphatase. Table I generally describes the experiment: TABLE I
Test Tube No. Contents Reaction rests
1 AP+BCIP+NBT No detection color change within 1 hr.
2 AP+BCIP+MTT+PMS Instantaneous detection color change 3 AP+MTT+PMS No detection color change within 1 hr.
4 AP+BCIP+MTT No detection color change within 1 hr.
In the experiment 5 ul of alkaline phosphatase from a concentrated aqueous stock solution was added to each of four test tubes. The alkaline phosphatase was colorless in solution. Next, from a 50 mg/ml aqueous stock solution of BCIP, 5 ul of BCIP (an excess amount) was added to each of test tubes numbers 1, 2, and 4 containing alkaline phosphatase. The BCIP was colorless in solution and when mixed with the alkaline phosphatase, the mixture remained colorless. Next, 10 ul of NBT solution, a lemon yellow solution, was added to Test Tube No. 1 which changed the previously colorless solution of BCIP and alkaline phosphatase to a lemon yellow color indicating the presence of NBT but not alkaline phosphatase as there was no deep color change produced within one hour of NBT being placed in admixture with the BCIP and alkaline phosphatase. Next, a lOmM aqueous stock solution of PMS (a faint tanish color solution) and a lOmM aqueous stock solution of MTT (a yellowish color solution) was prepared. To Test Tube No. 2 containing 5 ul of alkaline phosphatase and 5 ul of BCIP, there was added 5 ul of the stock solution of PMS and 5 ul of the stock solution of MTT which resulted in an instantaneous color change of the solution to a purplish/black deep colored solution, the solution later having settled formazan, indicative of the presence of alkaline phosphatase. Next, 5 ul of stock solution of PMS and 5 ul of the stock solution of MTT was added to Test Tube No. 3 containing 5 ul of alkaline phosphatase (no BCIP present). This addition changed the previously colorless alkaline phosphatase solution to a lemon yellow color indicating the presence of MTT but not alkaline phosphatase as there was no deep color change produced within one hour. Finally, 5 ul of MTT was added to Test Tube No. 4 containing 5 ul of alkaline phosphatase solution and 5 ul of BCIP solution. This addition changed the previously colorless alkaline phosphatase and BCIP solution to a lemon yellow color indicating the presence of MTT but not alkaline phosphatase as there was no deep color change produced within one hour.
EXAMPLE III Another experiment was performed similar to Example II but using a Whatman filter paper instead of test tubes. Table II below generally describes the experiment:
TABLE II
Whatman Filter Paper Contents Spot No. Added Reaction rests
1 AP+BCIP+NBT No formazan within 1 hour
2 AP+BCIP+MTT+PMS Dark purple formazan complex within 1 minute
3 AP+MTT+PMS No formazan within 1 hour 4 AP+BCIP+MTT No formazan within 1 hour
This experiment utilized the aqueous stock solutions of alkaline phosphatase, PMS, and MTT described in Example II above. Four spots of 5 ul of alkaline phosphatase solution was added to separate locations of one sheet of Whatman filter. Next, from the 50 mg/ml aqueous stock solution of BCIP referred to in Example II above, 5 ul of BCIP (an excess amount) was added to alkaline phosphatase spots numbers 1, 2, and 4. Then 10 ul of NBT was added to spot number 1. The addition of NBT left a yellowish stain but did not result in the formation of a color formazan within one hour. Next, 5 ul of stock solution of MTT and 5 ul of PMS was added to spot 2 (alkaline phosphatase and BCIP). This resulted in the formation of a dark purple formazan complex at the spot in less than one minute. To spot number 3 (having no BCIP) was added 5 ul of MTT, which resulted in a yellowish stain on the spot. Then 5 ul of PMS was added to spot number 3 which stained the spot with a faint brownish color stain in combination with the MTT but resulted in no colored formazan being produced within one hour. Next to spot number 4 was added 5 ul of BCIP and 5 ul of MTT which left a yellowish stain to the previously white paper but did not result in the formation of a colored formazan after one hour.
EXAMPLE IV This is a prophetic example relating to the identification of proteins synthesized by recombinant gene. First, a cloned bacteria, such as E-coli is grown and transferred to nitrocellulose paper or, alternatively, an extraction of proteins from a cloned bacteria is performed by SDS-gel. Next, the E-coli is lysed with chloroform or, alternatively, a western blotting of proteins on the nitrocellulose paper is performed which results in protein being affixed to the nitrocellulose paper from lysed bacteria or SDS-gel respectively. For example, the protein can be a protein of metabolized drug of abuse or a protein of a viral disease. Next, a first antibody, for example an antibody specific for glycoprotein 120 or the antibody against Lyme disease, is bound to the protein to be detected from the cloned bacteria to form a first antibody-protein complex. Next, a second antibody, such as a blotting grade conjugate of goat anti-mouse IgG, goat anti-rabbit IgG, or goat anti-human IgG, conjugated with alkaline phosphatase is bound to the first antibody-protein complex to form a first and second antibody and alkaline phosphatase complex. Next, a positive detection of the protein is made by the addition of a solution of BCIP and MTT and PMS to the complex sufficient to generate a chromogenic deep color change or a purple/blue formazan indicative of the presence and concentration of the protein.
The experiments set forth in EXAMPLES I, II, and III, above demonstrate the surprisingly superior ability of a mixture of BCIP, PMS, and MTT, in combination, to detect alkaline phosphatase. Examples II and III are specifically intended as being universal demonstrations of the applicability of a mixture of BCIP, PMS, and MTT, in combination, to chromogenically detect alkaline phosphatase when alkaline phosphatase is used in any system for detection purpose. One skilled in the art will therefore appreciate that the method of chromogenic detection of the present invention (and solution and composition therefor) may be used in any system utilizing alkaline phosphatase as a label including, for example, such a system addressed to inorganic analyte detection. It will be understood that the specification and examples are illustrative but not limitative of the present invention and that other embodiments within the spirit and scope of the invention will suggest themselves to those skilled in the art. Many modifications and variations of the invention as heretofore set forth can be made without departing from the scope thereof and therefore only such limitations should be imposed as are indicated by the appended claims.
INDUSTRIAL APPLICABILITY
The method of detection of the present invention has great sensitivity, namely 10 minu" 1S power, and the reaction, which can be completed in approximately twenty minutes, produces a purple formazan or a color change visible by the naked eye in from less than five minutes to approximately fifteen minutes compared to conventional BCIP-NBT detection techniques sensitive to 10 m±nuβ 12 power which may take many hours or over a day to complete and four or more hours to visually observe. Further, the present invention requires no radioisotope labelling and its sensitivity and specificity makes it useful for hybridization techniques where radioactive labelling and autoradiography are normally required. Also, the method of detection of the present invention can be used for nucleic acid transfers for colony, plaque, in vitro, and in situ hybridizations including standard Southern, Northern, Western, and Southwestern blotting techniques provided such transfers or techniques utilize alkaline phosphatase for chromogenic detection. Further, the present invention may not require use of amplification techniques. Further, the present invention requires no stabilizing agent for the tetrazolium salt and produces an irreversible reaction. Still further, the present invention is cost and economy advantageous as it may use only one-tenth of certain chemicals in solution compared to prior art techniques.

Claims

CLAIMSI claim:
1. A non-radioactive method of detecting a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto comprising reacting said complex with bromo-chloro-indolyl phosphate, phenazine methosulfate, and dimethylthiazol diphenyl tetrazolium and allowing the reaction to proceed to produce a colored formazan or a color change indicative of the presence of said labelled complex.
2. The method of claim 1 wherein said ligand is selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten.
3. The method of claim 1 wherein said antiligand is selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten
4. The method of claim 2 wherein said ligand is an antigen and said antiligand is an antibody specific for said antigen.
5. The method of claim 2 wherein said ligand is a hapten and said antiligand is an antibody specific for said hapten.
6. The method of claim 2 wherein said ligand is an antibody and said antiligand is an antigen specific for said antibody.
7. The method of claim 2 wherein said ligand is a protein and said antiligand is an antibody specific for said protein.
8. The method of claim 2 wherein said ligand is a nucleic acid and said antiligand is a complimentary nucleic acid specific for said nucleic acid.
9. The method of claim 2 wherein said ligand is an antibody complex and said antiligand is an antigen specific for said antibody complex.
10. The method of claim 1 wherein a ligand directly labelled with alkaline phosphatase and a tracer selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten compete for binding sites on said antiligand.
11. The method of claim 1 wherein a ligand selected from the group consisting of an antigen, an analyte, a protein, an antibody, an antibody complex, and a hapten and a tracer having alkaline phosphatase conjugated thereto compete for binding sites on said antiligand.
12. The method of claim 1 wherein the amount, intensity, or degree of produced colored formazan or color change is determined visually or instrumentally.
13. The method of claim 1 wherein the complex is reacted with a mixture containing in combination bromo-chloro-indolyl phosphate, phenazine methosulfate, and dimethylthiazol diphenyl tetrazolium.
14. The method of claim 13 wherein said mixture further includes a buffer.
15. The method of claim 14 wherein said buffer is distilled water.
16. The method of claim 14 wherein said buffer is a mixture in solution of Tris-HCl or Tris-base, sodium chloride, and magnesium chloride.
17. The method of Claim 14 wherein the buffer has a pH of 7 to 11.
18. The method of Claim 14 wherein the buffer has a pH of 9.5.
19. A solution for the detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested comprising a mixture of bromo-chloro- indolyl phosphate, phenazine methosulfate, and dimethylthiazol diphenyl tetrazolium which when added to said test sample is capable of producing a colored formazan or a color change indicative of the presence of said labelled complex.
20. The solution of Claim 19 containing approximately equal amounts of phenazine methosulfate and dimethylthiazol diphenyl tetrazolium in combination with an excess of bromo- chloro-indolyl phosphate.
21. The solution of Claim 19 wherein the ratio of bromo- chloro-indolyl phosphate, phenazine methosulfate, and dimethylthiazol diphenyl tetrazolium respectively in said solution is about 6:1:1 by weight.
22. The solution of Claim 19 including from about 35 to 50 microliters of bromo-chloro-indolyl phosphate from a 50 mg/ml aqueous solution, from about 70 to 100 microliters of phenazine methosulfate from a lOmM aqueous solution and from about 70 to 100 microliters of dimethylthiazol diphenyl tetrazolium from a lOmM aqueous solution.
23. The solution of Claim 19 capable of producing a sufficient colored formazan or a color change indicative of the presence or concentration of said complex within fifteen minutes of contacting at ambient temperature said test sample.
24. The solution of Claim 19 wherein the amount, intensity, or degree of the produced colored formazan or color change is sufficient to accurately determine visually or instrumentally the presence or concentration of said complex in said test sample.
25. The solution of Claim 19 further including a buffer.
26. The solution of Claim 25 wherein the buffer is distilled water.
27. The solution of Claim 25 wherein the buffer is a mixture in solution of Tris-HCl or Tris-base, sodium chloride, and magnesium chloride.
28. The solution of Claim 25 wherein the buffer has a pH of 7 to 11.
29. The solution of Claim 25 wherein the buffer has a pH of 9.5.
30. A composition for the detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto in a sample to be tested comprising a mixture of bromo-chloro- indolyl phosphate, phenazine methosulfate, and dimethylthiazol diphenyl tetrazolium which when dissolved in solution and added to said test sample is capable of producing a colored formazan or a color change indicative of the presence of said labelled complex.
31. The composition of Claim 30 in powder form.
32. The composition of Claim 30 in solid form.
33. The composition of Claim 30 further including an inert carrier.
34. The composition of Claim 30 wherein the inert carrier is soluble in water.
35. The composition of Claim 30 wherein the inert carrier is mannitol.
36. The composition of Claim 30 containing approximately equal amounts of phenazine methosulfate and dimethylthiazol diphenyl tetrazolium in combination with an excess of bromo- chloro-indolyl phosphate.
37. The composition of Claim 30 wherein the ratio of bromo-chloro-indolyl phosphate, phenazine methosulfate, and dimethylthiazol diphenyl tetrazolium respectively in said composition is about 6:1:1 by weight.
38. A kit of materials for performing the method of detection of a ligand and antiligand complex labelled with alkaline phosphatase or a tracer having alkaline phosphatase conjugated thereto according to claim 1, comprising a vial or packet of bromo-chloro-indolyl phosphate, phenazine methosulfate, and dimethylthiazol diphenyl tetrazolium in an amount sufficient, when reacted with said labelled complex, to produce a colored formazan or a color change indicative of the presence of said labelled complex.
PCT/US1994/001224 1993-01-28 1994-01-28 Non-radioactive method for detecting a labelled segment and a solution or composition therefor WO1994017211A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU62349/94A AU6234994A (en) 1993-01-28 1994-01-28 Non-radioactive method for detecting a labelled segment and a solution or composition therefor
EP94909532A EP0701626A4 (en) 1993-01-28 1994-01-28 Non-radioactive method for detecting a labelled segment and a solution or composition therefor
CA002155028A CA2155028C (en) 1993-01-28 1994-01-28 Non-radioactive method for detecting a labelled segment and a solution or composition therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/010,344 1993-01-28
US08/010,344 US5354658A (en) 1993-01-28 1993-01-28 Non-radioactive method for detecting a labelled segment and a solution or composition therefor

Publications (1)

Publication Number Publication Date
WO1994017211A1 true WO1994017211A1 (en) 1994-08-04

Family

ID=21745300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/001224 WO1994017211A1 (en) 1993-01-28 1994-01-28 Non-radioactive method for detecting a labelled segment and a solution or composition therefor

Country Status (5)

Country Link
US (2) US5354658A (en)
EP (1) EP0701626A4 (en)
AU (1) AU6234994A (en)
CA (1) CA2155028C (en)
WO (1) WO1994017211A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354658A (en) * 1993-01-28 1994-10-11 Dennis Wright Non-radioactive method for detecting a labelled segment and a solution or composition therefor
US5874216A (en) * 1996-02-23 1999-02-23 Ensys Environmental Products, Inc. Indirect label assay device for detecting small molecules and method of use thereof
US5916746A (en) * 1996-05-09 1999-06-29 Kirkegaard & Perry Laboratories, Inc. Formazan-based immunoassay
US6225074B1 (en) * 1997-08-18 2001-05-01 Dennis Wright Direct chloramphenicol acetyl transferase assay
GB0105362D0 (en) * 2001-03-05 2001-04-18 Univ Sunderland Assay
US6686202B2 (en) 2001-08-08 2004-02-03 Placer Dome, Inc. Methods for detecting and extracting gold
WO2008094202A2 (en) * 2006-07-27 2008-08-07 Jonathan Roth Methodology for detection, enumeration, propagation and manipulation of bacteriophages
JP6104165B2 (en) * 2011-09-30 2017-03-29 ライオン株式会社 Method for measuring color change of redox indicator
KR101415951B1 (en) * 2012-06-22 2014-07-04 이손이엔엘 (주) Estimation Method for ecotoxicity of copper and mercury using inhibition of Iodonitrotetrazolium-dehydrogenase
US9433282B2 (en) 2013-09-25 2016-09-06 Hni Technologies Inc. Connector hub and modular work system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748111A (en) * 1984-03-12 1988-05-31 Molecular Diagnostics, Inc. Nucleic acid-protein conjugate used in immunoassay
US5053336A (en) * 1989-07-17 1991-10-01 Regents Of The University Of California Monoclonal antibodies for the separate detection of halodeoxyuridines and method for their use
US5082780A (en) * 1989-09-12 1992-01-21 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215197A (en) * 1978-08-04 1980-07-29 Miles Laboratories, Inc. Test means and method for creatinine determination
JPS5768798A (en) * 1980-10-14 1982-04-27 Toyo Jozo Co Ltd Novel measurement of amylase activity
DE3048662A1 (en) * 1980-12-23 1982-07-22 Boehringer Mannheim Gmbh, 6800 Mannheim STABILIZED PREPARATION OF TETRAZOLIUM SALTS
NZ199380A (en) * 1981-12-23 1986-08-08 J R Baker Determination of serum glucose levels in blood samples
US4849347A (en) * 1984-11-29 1989-07-18 Hoffmann-La Roche Inc. Colorimetric biological assay
US4847194A (en) * 1987-03-13 1989-07-11 Becton, Dickinson And Company Colorimetric detection of delta-5-3-ketosteroid isomerase and immunoassay based thereon
IL85018A0 (en) * 1988-01-03 1988-06-30 Orgenics Ltd Stable chromogenic substrate mixture of indoxyl phosphate and tetrazolium salt,method of making and using same in biological and diagnostic assays
US5188938A (en) * 1988-12-29 1993-02-23 Microgenics Corporation Enzyme quantitation wicking assay
US4978613A (en) * 1989-01-17 1990-12-18 Abbott Laboratories Beta-lactamase assay employing chromogenic precipitating substrates
US4956301A (en) * 1989-11-02 1990-09-11 Miles Inc. Test device and method of assaying for fructosamines
US5139934A (en) * 1990-05-25 1992-08-18 Becton, Dickinson And Company Substrate composition and method for solid phase urease immunoassay
US5225328A (en) * 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5354658A (en) * 1993-01-28 1994-10-11 Dennis Wright Non-radioactive method for detecting a labelled segment and a solution or composition therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748111A (en) * 1984-03-12 1988-05-31 Molecular Diagnostics, Inc. Nucleic acid-protein conjugate used in immunoassay
US5053336A (en) * 1989-07-17 1991-10-01 Regents Of The University Of California Monoclonal antibodies for the separate detection of halodeoxyuridines and method for their use
US5082780A (en) * 1989-09-12 1992-01-21 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Analytical Biochemistry, Volume 136, issued 1984, BLAKE et al., "A Rapid, Sensitive Method for Detection of Alkaline Phosphatase-Conjugated Anti-Antibody of Western Blots", pages 175-179, see pages 175-177. *
Applied and Theorical Electrophoresis, Volume 1, issued 1990, HEEGAARD N., "Visualization of Alkaline Phospl. by Means of Formazan Staining", pages 261-264, see entire document. *
Histochemistry, Volume 75, issued 1982, KUGLER P., "Quantitative Dehydrogenase Histochemistry with Exogenous Electron Carriers (PMS, MPMS, MB)", pages 99-112, see pages 99-102. *
Neuroscience Research, Volume 9, issued 1990, KIYAMA et al., "Recent Progress in the Use of the Technique of Non-Radioactive in Situ Hybridization Histochemistry; New Tools for Molecular Neurobiology", pages 1-21, see entire document. *
See also references of EP0701626A4 *

Also Published As

Publication number Publication date
EP0701626A1 (en) 1996-03-20
US5354658A (en) 1994-10-11
AU6234994A (en) 1994-08-15
CA2155028C (en) 1999-10-12
EP0701626A4 (en) 1998-04-29
CA2155028A1 (en) 1994-08-04
US5670327A (en) 1997-09-23

Similar Documents

Publication Publication Date Title
US4904583A (en) Cascade immunoassay by multiple binding reactions
EP0444302B1 (en) Method of immunoassay including deactivation of endogenous alkaline phosphatase
US5328831A (en) Substrate composition for solid phase urease immunoassay
US5639609A (en) Method for immobilizing nucleic acids using modified capture probes
EP0156641A2 (en) Enzymic method of detecting analytes and novel substrates therefor
US5354658A (en) Non-radioactive method for detecting a labelled segment and a solution or composition therefor
EP0775215B1 (en) Chemiluminescence assays based on indoxyl substrates or thioindoxyl substrates
US6326136B1 (en) Macromolecular conjugate made using unsaturated aldehydes
US6362328B1 (en) Assays and probes with enzyme labels
US5916746A (en) Formazan-based immunoassay
EP0799421B1 (en) Differential timing method for detecting multiple analytes in a test sample
US4847194A (en) Colorimetric detection of delta-5-3-ketosteroid isomerase and immunoassay based thereon
Gillam Non-radioactive probes for specific DNA sequences
US5871906A (en) Method for detection of amplified nucleic acid products and related diagnostic assays
Pereira Non‐radioactive nucleic acid probes for the diagnosis of virus infections
US7291474B2 (en) Hydrolytic substrates for an analyte-dependent enzyme activation system
US5202233A (en) Process for the detection of substances with hydrolase activity
US6159699A (en) Enzyme linked chemiluminescent assay
JPH08501446A (en) Conjugate for detecting and / or measuring biological compound
JP3658820B2 (en) Method for detecting ligand in sample and reagent therefor
CA1339353C (en) Macromolecular conjugate
EP0386690A1 (en) Signal enhancement in magnetic immunoassay by inhibition of enzymatic catalysis
JPH0970288A (en) New alkaline phosphatase
NO844846L (en) HYBRIDIZATION ANALYSIS USING A LABELED TEST AND ANTI-HYBRID
Rashtchian Alkaline Phosphatase by Colorimetry

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2155028

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994909532

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994909532

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994909532

Country of ref document: EP